We have located links that may give you full text access.
Management of Mutrashmari (urolithiasis) with Palasha Kshara and Ashmarihara Kwatha : An open-labelled placebo-controlled clinical trial.
Ayu 2022
BACKGROUND: Mutrashmari (urolithiasis), a pathological condition of the urinary system where aggregation of urinary crystalloids takes place anywhere in the urinary tract, i.e., from the kidney to urinary bladder showing male preponderance (male:female = 2:1) and now becoming medico-surgical as well as economical challenge for all health-care systems.
AIMS: The aim of this study is to evaluate the effect of Palasha Kshara (alkali) with Ashmarihara Kwatha (decoction) in the management of Mutrashmari (urolithiasis).
MATERIALS AND METHOD: Thirty-nine patients of Mutrashmari were selected and randomly allocated with a computerized randomized method into two groups. In trial group A ( n = 20), capsule Palasha Kshara ( Mridu ), 500 mg three times a day after meal, and Ashmarihara Kwatha (decoction) (40 ml twice daily) were given orally after meals for 2 months. In placebo control group B ( n = 19), placebo capsule (granulated wheat), was given in a dosage of 500 mg along with 3-4 l of water for 2 months.
RESULTS: Patients of Palasha Kshara and Ashmarihara Kwatha group showed better relief in chief complaints, i.e., pain and increased frequency of micturition as compared to the placebo group. Complete remission of symptoms of Mutrashmari was more in patients treated with Palasha Kshara with Ashmarihara decoction.
CONCLUSION: Palasha Kshara with Ashmarihara Kwatha is found more effective than placebo in the management of Mutrashmari (urolithiasis).
AIMS: The aim of this study is to evaluate the effect of Palasha Kshara (alkali) with Ashmarihara Kwatha (decoction) in the management of Mutrashmari (urolithiasis).
MATERIALS AND METHOD: Thirty-nine patients of Mutrashmari were selected and randomly allocated with a computerized randomized method into two groups. In trial group A ( n = 20), capsule Palasha Kshara ( Mridu ), 500 mg three times a day after meal, and Ashmarihara Kwatha (decoction) (40 ml twice daily) were given orally after meals for 2 months. In placebo control group B ( n = 19), placebo capsule (granulated wheat), was given in a dosage of 500 mg along with 3-4 l of water for 2 months.
RESULTS: Patients of Palasha Kshara and Ashmarihara Kwatha group showed better relief in chief complaints, i.e., pain and increased frequency of micturition as compared to the placebo group. Complete remission of symptoms of Mutrashmari was more in patients treated with Palasha Kshara with Ashmarihara decoction.
CONCLUSION: Palasha Kshara with Ashmarihara Kwatha is found more effective than placebo in the management of Mutrashmari (urolithiasis).
Full text links
Related Resources
Trending Papers
Hemodynamic Support in Sepsis.Anesthesiology 2024 June 2
The New Challenge of Obesity - Obesity-Associated Nephropathy.Diabetes, Metabolic Syndrome and Obesity 2024
Advances in Clinical Cardiology 2023: A Summary of Key Clinical Trials.Advances in Therapy 2024 May 15
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app